Format

Send to

Choose Destination
Exp Cell Res. 2017 Jul 15;356(2):160-165. doi: 10.1016/j.yexcr.2017.05.004. Epub 2017 May 5.

Therapeutic targeting of the HIF oxygen-sensing pathway: Lessons learned from clinical studies.

Author information

1
Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; Departments of Cancer Biology, and Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN, USA. Electronic address: volker.haase@vanderbilt.edu.

Abstract

The oxygen-sensitive hypoxia-inducible factor (HIF) pathway plays a central role in the control of erythropoiesis and iron metabolism. The discovery of prolyl hydroxylase domain (PHD) proteins as key regulators of HIF activity has led to the development of inhibitory compounds that are now in phase 3 clinical development for the treatment of renal anemia, a condition that is commonly found in patients with advanced chronic kidney disease. This review provides a concise overview of clinical effects associated with pharmacologic PHD inhibition and was written in memory of Professor Lorenz Poellinger.

KEYWORDS:

Anemia; Chronic kidney disease; Clinical trials; Hypoxia; Hypoxia-inducible factor; Oxygen; Prolyl hydroxylase domain

PMID:
28483447
PMCID:
PMC5507591
DOI:
10.1016/j.yexcr.2017.05.004
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center